相似文献
1
Sphingolipid signaling in metabolic disorders.
Cell Metab. 2012 Oct 3;16(4):420-34. doi: 10.1016/j.cmet.2012.06.017. Epub 2012 Sep 13.
2
p53 and regulation of bioactive sphingolipids.
Adv Enzyme Regul. 2011;51(1):219-28. doi: 10.1016/j.advenzreg.2010.10.003. Epub 2010 Oct 28.
3
Sphingolipids and Lipoproteins in Health and Metabolic Disorders.
Trends Endocrinol Metab. 2017 Jul;28(7):506-518. doi: 10.1016/j.tem.2017.03.005. Epub 2017 Apr 24.
4
Genetic diseases of sphingolipid metabolism: pathological mechanisms and therapeutic options.
FEBS Lett. 2006 Oct 9;580(23):5510-7. doi: 10.1016/j.febslet.2006.08.041. Epub 2006 Sep 1.
5
Sphingolipids in metabolic disease: The good, the bad, and the unknown.
Cell Metab. 2021 Jul 6;33(7):1293-1306. doi: 10.1016/j.cmet.2021.06.006.
6
Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
Endocr Rev. 2008 Jun;29(4):381-402. doi: 10.1210/er.2007-0025. Epub 2008 May 1.
7
Potential therapeutic targets for atherosclerosis in sphingolipid metabolism.
Clin Sci (Lond). 2019 Mar 19;133(6):763-776. doi: 10.1042/CS20180911. Print 2019 Mar 29.
8
Medicinal chemistry aspects of drug targets in sphingolipid metabolism.
ChemMedChem. 2008 Apr;3(4):543-51. doi: 10.1002/cmdc.200700252.
9
Sphingolipid metabolism and neutral sphingomyelinases.
Handb Exp Pharmacol. 2013(215):57-76. doi: 10.1007/978-3-7091-1368-4_3.
10
Probing compartment-specific sphingolipids with targeted bacterial sphingomyelinases and ceramidases.
J Lipid Res. 2019 Nov;60(11):1841-1850. doi: 10.1194/jlr.M094722. Epub 2019 Jun 26.
引用本文的文献
1
The relationship between plasma sphingosine-1-phosphate, plasma apolipoprotein M, obesity, and the risk of incident type 2 diabetes: a prospective cohort study.
Int J Obes (Lond). 2025 Aug 26. doi: 10.1038/s41366-025-01890-7.
2
Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases.
World J Cardiol. 2025 Jul 26;17(7):106561. doi: 10.4330/wjc.v17.i7.106561.
3
A Novel Missense Variant in Ultrarare SLC35A1-CDG Alters Cellular Glycosylation, Lipid, and Energy Metabolism Without Affecting CDG Serum Markers.
Hum Mutat. 2025 Jun 26;2025:6290620. doi: 10.1155/humu/6290620. eCollection 2025.
4
Dissecting inflammation in the immunemetabolomic era.
Cell Mol Life Sci. 2025 Apr 28;82(1):182. doi: 10.1007/s00018-025-05715-8.
5
Inhibition of ceramide synthesis improves the outcome of ischemia/reperfusion injury in cardiomyocytes derived from human induced pluripotent stem cell.
Stem Cell Res Ther. 2025 Apr 18;16(1):190. doi: 10.1186/s13287-025-04340-3.
6
Ceramide in Coronary Artery Disease: Troublesome or Helpful Future Tools in the Assessment of Risk Prediction and Therapy Effectiveness?
Metabolites. 2025 Mar 1;15(3):168. doi: 10.3390/metabo15030168.
7
The metabolome of male and female individuals with knee osteoarthritis is influenced by 18-months of weight loss intervention: the IDEA trial.
BMC Musculoskelet Disord. 2024 Dec 20;25(1):1057. doi: 10.1186/s12891-024-08166-7.
8
Gut microbiota metabolism of branched-chain amino acids and their metabolites can improve the physiological function of aging mice.
Aging Cell. 2025 Apr;24(4):e14434. doi: 10.1111/acel.14434. Epub 2024 Dec 4.
9
Emerging Roles for Sphingolipids in Cardiometabolic Disease: A Rational Therapeutic Target?
Nutrients. 2024 Sep 28;16(19):3296. doi: 10.3390/nu16193296.
10
Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis.
Metabolites. 2024 Sep 16;14(9):499. doi: 10.3390/metabo14090499.
本文引用的文献
1
The Sjögren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of the sphingosine 1-phosphate degradation pathway.
Mol Cell. 2012 May 25;46(4):461-71. doi: 10.1016/j.molcel.2012.04.033.
2
Structural, mechanistic and regulatory studies of serine palmitoyltransferase.
Biochem Soc Trans. 2012 Jun 1;40(3):547-54. doi: 10.1042/BST20110769.
3
Plasma membrane stress induces relocalization of Slm proteins and activation of TORC2 to promote sphingolipid synthesis.
Nat Cell Biol. 2012 Apr 15;14(5):542-7. doi: 10.1038/ncb2480.
4
The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice.
J Clin Invest. 2012 Apr;122(4):1416-26. doi: 10.1172/JCI60746. Epub 2012 Mar 12.
5
Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.
Annu Rev Immunol. 2012;30:69-94. doi: 10.1146/annurev-immunol-020711-075011. Epub 2011 Dec 5.
6
Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?
Diabetologia. 2012 Feb;55(2):421-31. doi: 10.1007/s00125-011-2384-1. Epub 2011 Nov 29.
7
Protein kinase Ypk1 phosphorylates regulatory proteins Orm1 and Orm2 to control sphingolipid homeostasis in Saccharomyces cerevisiae.
Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19222-7. doi: 10.1073/pnas.1116948108. Epub 2011 Nov 11.
8
Ceramides as modulators of cellular and whole-body metabolism.
J Clin Invest. 2011 Nov;121(11):4222-30. doi: 10.1172/JCI57144. Epub 2011 Nov 1.
9
Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1.
J Clin Invest. 2011 Dec;121(12):4735-45. doi: 10.1172/JCI57549.
10
The debut of a rational treatment for an inherited neuropathy?
J Clin Invest. 2011 Dec;121(12):4624-7. doi: 10.1172/JCI60511.
Zotero 插件